New cardiac MRI analyses assessing regional effects of ATTR depleter cliramitug to be presented at ESC Congress 2026
Neurimmune today announced that new cardiac MRI analyses assessing the regional effects of cliramitug on cardiac amyloid depletion, structure and function in participants from the Phase 1b study will be presented at ESC Congress 2026 in Munich.
Presentation Details
Title: The importance of distinct cardiac MRI regional analyses to assess the effects of cliramitug on amyloid depletion from the Phase 1b study NI006-101
Presenter: Fabian aus dem Siepen (University Hospital Heidelberg - Heidelberg, Germany)
Session: Heart failure redefined: hypertrophic cardiomyopathy and transthyretin amyloid cardiomyopathy precision treatments
Date: August 30, 2026
Time: 09:15-10:00
Location: Station 5 (Research Gateway – Hall A1)
ATTR-CM is a systemic and potentially life-threatening disease caused by the deposition of misfolded transthyretin (TTR), which presents with progressive heart failure. Despite advances in slowing disease progression, there is currently no available treatment option designed to deplete TTR from the heart to revert cardiac dysfunction.
Cliramitug is an investigational human monoclonal antibody designed to deplete amyloid deposits from the affected heart in ATTR-CM.1 In Study NI006-101, treatment with cliramitug for more than a year was not associated with apparent drug-related serious adverse events, and surrogate markers of cardiac amyloid load indicated cardiac ATTR depletion along with improvement of cardiac biomarkers and function.2,3
In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca Rare Disease for cliramitug. Neurimmune is responsible for the Phase 1 study (NI006-101) and the Phase 2 follow-on study (NI006-102, EXCEL), on behalf of Alexion. Alexion is responsible for further clinical development, manufacturing, and commercialization of cliramitug, including the ongoing DepleTTR-CM Phase 3 trial to evaluate the safety and efficacy of cliramitug in adults with ATTR-CM.
1 Michalon et al., Nat Commun 2021; 12(1):3142.
2 Garcia-Pavia et al., N Engl J Med 2023; 389(3):239.
3 Kahr et al., Nature Medicine 2026; 32:2639.
About Neurimmune
Neurimmune is a clinical-stage biopharmaceutical company building next-generation antibody therapeutics. The company pioneers amyloid depletion as a novel therapeutic mechanism to treat CNS and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis and ATTR cardiomyopathy. Neurimmune discovered the anti-ATTR antibody cliramitug (formerly NI006, ALXN2220, Phase 3) for ATTR cardiomyopathy, the anti-misfolded SOD1 antibody AP-101 (Phase 2) for ALS, the anti-NogoA antibody NG004 (Phase 1) for spinal cord injury and the anti-amyloid light chain antibody NI009 (preclinical) for AL amyloidosis.
Contact for Media
Camilla White (US)
camilla.white@dgagroup.com
Martin Meier-Pfister (Switzerland)
media@neurimmune.com